Relmada Therapeutics Inc (RLMD)
3.35
-0.14
(-4.01%)
USD |
NASDAQ |
May 17, 16:00
3.35
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics Enterprise Value: 17.17M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 17.17M |
| May 16, 2024 | 21.70M |
| May 15, 2024 | 21.39M |
| May 14, 2024 | 26.22M |
| May 13, 2024 | 22.90M |
| May 10, 2024 | 22.90M |
| May 09, 2024 | 31.05M |
| May 08, 2024 | 31.95M |
| May 07, 2024 | 31.65M |
| May 06, 2024 | 32.56M |
| May 03, 2024 | 27.43M |
| May 02, 2024 | 28.64M |
| May 01, 2024 | 27.73M |
| April 30, 2024 | 26.22M |
| April 29, 2024 | 22.90M |
| April 26, 2024 | 31.95M |
| April 25, 2024 | 28.03M |
| April 24, 2024 | 32.86M |
| April 23, 2024 | 34.37M |
| April 22, 2024 | 33.16M |
| April 19, 2024 | 37.08M |
| April 18, 2024 | 46.14M |
| April 17, 2024 | 57.60M |
| April 16, 2024 | 53.98M |
| April 15, 2024 | 50.66M |
| Date | Value |
|---|---|
| April 12, 2024 | 56.70M |
| April 11, 2024 | 57.00M |
| April 10, 2024 | 52.47M |
| April 09, 2024 | 61.22M |
| April 08, 2024 | 63.03M |
| April 05, 2024 | 54.89M |
| April 04, 2024 | 57.90M |
| April 03, 2024 | 58.51M |
| April 02, 2024 | 65.45M |
| April 01, 2024 | 63.64M |
| March 28, 2024 | 43.99M |
| March 27, 2024 | 42.18M |
| March 26, 2024 | 45.19M |
| March 25, 2024 | 51.53M |
| March 22, 2024 | 50.32M |
| March 21, 2024 | 44.29M |
| March 20, 2024 | 37.50M |
| March 19, 2024 | 65.71M |
| March 18, 2024 | 70.24M |
| March 15, 2024 | 67.22M |
| March 14, 2024 | 55.08M |
| March 13, 2024 | 73.44M |
| March 12, 2024 | 70.12M |
| March 11, 2024 | 77.35M |
| March 08, 2024 | 94.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-118.84M
Minimum
Dec 08 2022
876.17M
Maximum
Sep 30 2022
276.76M
Average
332.68M
Median
Jun 08 2022
Enterprise Value Benchmarks
| Cyclacel Pharmaceuticals Inc | -0.3591M |
| Lifecore Biomedical Inc | -- |
| Harrow Inc | 700.82M |
| Corvus Pharmaceuticals Inc | 121.11M |
| Aquestive Therapeutics Inc | 216.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.83M |
| Total Expenses (Quarterly) | 22.99M |
| EPS Diluted (Quarterly) | -0.72 |
| Earnings Yield | -93.41% |
| Normalized Earnings Yield | -1.037 |